rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MAIA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
      Oct 8BenzingaRLMDMAIA
      MAIA Biotechnology Releases New Investor Presentation and Update

      Detailed price information for Maia Biotechnology Inc (MAIA-A) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailMAIA
      MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
      Oct 7Yahoo FinanceMAIA
      Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
      Oct 1Yahoo FinanceMAIA
      MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
      Sep 23Yahoo FinanceMAIA
      MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
      Sep 22Yahoo FinanceMAIA
      MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

      Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that

      Sep 16Yahoo FinanceMAIA
      Maia Biotechnology CEO Vlad Vitoc buys $100,010 in company stock
      Sep 15Investing.comMAIA
      MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
      Sep 15Yahoo FinanceMAIA
      Maia Biotechnology director buys $49,516 in company shares
      Sep 14Investing.comMAIA
      MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026

      Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleoside

      Sep 10Yahoo FinanceMAIA
      Maia Biotechnology director Guerrero buys $2,386 in common stock
      Aug 26Investing.comMAIA

      This is the newest page. Registered accounts read further back.